Exaggerated QT prolongation after cardioversion of atrial fibrillation

Journal of the American College of Cardiology

Volumn 34, Issue 2, 1999, Pages 396-401

  Choy, Anna Maria J ^a   Darbar, Dawood ^a   Dell'Orto, Simonetta ^a   Roden, Dan M ^a  

^a VANDERBILT UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOFETILIDE;

ACTION POTENTIAL; ADULT; ARTICLE; CARDIOVERSION; CLINICAL ARTICLE; FEMALE; HEART ATRIUM FIBRILLATION; HEART RATE; HUMAN; MALE; PRIORITY JOURNAL; QT INTERVAL; TORSADE DES POINTES;

ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; ATRIAL FLUTTER; ELECTRIC COUNTERSHOCK; ELECTROCARDIOGRAPHY; FEMALE; HEART RATE; HUMANS; MALE; PHENETHYLAMINES; SULFONAMIDES;

EID: 0032744871     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(99)00226-0     Document Type: Article

References (38)

1. Hartel G., Louhija A., Konttinen A., Halonen P.I. Value of quinidine in maintenance of sinus rhythm after electric conversion of atrial fibrillation. Br Heart J. 32:1970;57-60.
2. Faber T.S., Zehender M., Van de Loo A., et al. Torsade de pointes complicating drug treatment of low-malignant forms of arrhythmia four cases reports . Clin Cardiol. 17:1994;197-202.
3. Arstall M.A., Hii J.T., Lehman R.G., Horowitz J.D. Sotalol-induced torsade de pointes management with magnesium infusion . Postgrad Med J. 68:1992;289-290.
4. Hohnloser S.H., Van de Loo A., Baedeker F. Efficacy and proarrhythmic hazards of pharmacologic cardioversion of atrial fibrillation prospective comparison of sotalol versus quinidine . J Am Coll Cardiol. 26:1995;852-858.
5. + current in cardiac myocytes by dofetilide. J Pharmacol Exp Ther. 262:1993;809-817.
6. Gwilt M., Arrowsmith J.E., Blackburn K.J., et al. UK-68,798 a novel, potent and highly selective class III antiarrhythmic agent which blocks potassium channels in cardiac cells . J Pharmacol Exp Ther. 256:1991;318-324.
7. Sedgwick M.L., Rasmussen H.S., Cobbe S.M. Clinical and electrophysiologic effects of intravenous dofetilide (UK-68,798), a new class III antiarrhythmic drug, in patients with angina pectoris. Am J Cardiol. 69:1992;513-517.
8. Echt D.S., Lee J.T., Murray K.T., et al. A randomized, double-blind, placebo-controlled, dose-ranging study of dofetilide in patients with inducible sustained ventricular tachyarrhythmias. J Cardiovasc Electrophysiol. 6:1995;687-699.
9. Falk R.H., Pollak A., Singh S.N., Friedrich T. Intravenous dofetilide, a class III antiarrhythmic agent, for the termination of sustained atrial fibrillation or flutter. J Am Coll Cardiol. 29:1997;385-390.
10. Sagnella G.A., Markandu N.D., Buckley M.G., et al. Plasma atrial natriuretic peptide, aldosterone, and plasma renin activity responses to gradual changes in dietary sodium intake. Am J Hypertens. 3:1990;863-865.
11. Darbar D., Fromm M.F., Dell'Orto S., et al. QT prolongation by quinidine is determined by sympathetic activation (abstr). Circulation. 98:1998;I27.
12. Riddell J.G., McAllister C.B., Wilkinson G.R., et al. A new method for constant plasma drug concentrations application to lidocaine . Ann Intern Med. 100:1984;25-28.
13. Crozier I., Richards A.M., Foy S.G., Ikram H. Electrophysiological effects of atrial natriuretic peptide on the cardiac conduction system in man. PACE Pacing Clin Electrophysiol. 16:1993;738-742.
14. Buja G., Miorelli M., Turrini P., et al. Comparison of QT dispersion in hypertrophic cardiomyopathy between patients with and without ventricular arrhythmias and sudden death. Am J Cardiol. 72:1993;973-976.
15. Choy A.M., Lang C.C., Chomsky D.M., et al. Normalization of acquired QT prolongation in humans by intravenous potassium. Circulation. 96:1997;2149-2154.
16. Suttorp M.J., Polak P.E., van 't Hof A., et al. Efficacy and safety of a new selective class III antiarrhythmic agent dofetilide in paroxysmal atrial fibrillation or atrial flutter. Am J Cardiol. 69:1992;417-419.
17. Sedgwick M.L., Lip G., Rae A.P., Cobbe S.M. Chemical cardioversion of atrial fibrillation with intravenous dofetilide. Int J Cardiol. 49:1995;159-166.
18. Carlsson L., Abrahamsson C., Andersson B., et al. Proarrhythmic effects of the class III agent almokalant importance of infusion rate, QT dispersion, and early afterdepolarisations . Cardiovasc Res. 27:1993;2186-2193.
19. Pai G.R., Rawles J.M. The QT interval in atrial fibrillation. Br Heart J. 61:1989;510-513.
20. Bazett H.C. An analysis of the time relations of electrocardiograms. Heart. 7:1920;353-370.
21. Sagie A., Larson M.G., Goldberg R.J., et al. An improved method for adjusting the QT interval for heart rate (the Framingham Heart Study). Am J Cardiol. 70:1992;797-801.
22. Davidowski T.A., Wolf S. The QT interval during reflex cardiovascular adaptation. Circulation. 69:1984;22-25.
23. Hondeghem L.M., Snyders D.J. Class III antiarrhythmic agents have a lot of potential, but a long way to go reduced effectiveness and dangers of reverse use-dependence . Circulation. 81:1990;686-690.
24. Ohler A., Amos G.J., Wettwer E., Ravens U. Frequency-dependent effects of E-4031, almokalant, dofetilide and tedisamil on action potential duration no evidence for "reverse use dependent" block . Naunyn Schmiedeberg Arch Pharmacol. 349:1994;602-610.
25. Bashir Y., Thomsen P.E.B., Kingma J.H., et al. Electrophysiologic profile and efficacy of intravenous dofetilide (UK-68,798), a new class III antiarrhythmic drug, in patients with sustained monomorphic ventricular tachycardia. Am J Cardiol. 76:1995;1040-1044.
26. Stambler B.S., Wood M.A., Ellenbogen K.A., et al. Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Circulation. 94:1996;1613-1621.
27. Wallin B.G., Delius W., Sundlof G. Human muscle nerve sympathetic activity in cardiac arrhythmias. Scand J Clin Lab Invest. 34:1974;293-300.
28. Salerno D.M., Katz A., Dunbar D.N., Fjeldos-Sperbeck K. Serum electrolytes and catecholamines after cardioversion from ventricular tachycardia and atrial fibrillation. PACE. 16:1993;1862-1871.
29. Arakawa M., Miwa H., Kambara K., et al. Changes in plasma concentrations of atrial natriuretic peptides after cardioversion of chronic atrial fibrillation. Am J Cardiol. 70:1992;550-552.
30. Sorbera L.A., Morad M. Atrionatriuretic peptide transforms cardiac sodium channels into calcium-conducting channels. Science. 247:1990;969-973.
31. + current in human atrial cells. Pflugers Arch. 421:1992;486-491.
32. Sanguinetti M.C., Jurkiewicz N.K., Scott A., Siegl P.K.S. Isoproterenol antagonizes prolongation of refractory period by the class III antiarrhythmic agent E-4031 in guinea pig myocytes mechanism of action . Circ Res. 68:1991;77-84.
33. Donger C., Denjoy I., Berthet M., et al. KVLQT1 C-terminal missense mutation causes a forme fruste long-QT syndrome. Circulation. 96:1997;2778-2781.
34. Roden D.M. Taking the idio out of idiosyncratic - predicting torsades de pointes. PACE Pacing Clin Electrophysiol. 21:1998;1029-1034.
35. Locati E.H., Maison-Blanche P., Dejode P., et al. Spontaneous sequences of onset of torsade de pointes in patients with acquired prolonged repolarization quantitative analysis of Holter recordings . J Am Coll Cardiol. 25:1995;1564-1575.
36. + current differential sensitivity to block by class III antiarrhythmic agents . J Gen Physiol. 96:1990;195-215.
37. Le Coz F., Funck-Brentano C., Poirier J.M., et al. Prediction of sotalol-induced maximum steady-state QTc prolongation from single-dose administration in healthy volunteers. Clin Pharmacol Ther. 52:1992;417-426.
38. Roden D.M. Early after-depolarizations and torsade de pointes implications for the control of cardiac arrhythmias by prolonging repolarization . Eur Heart J. 14:(Suppl H):1993;56-61.